BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Euro trading is green, but no volume

<< Previous

Bullboard Posts

Next >>

Comment by stckapprenticeon Nov 30, 2020 10:19am

30 Views

Post# 31999812

RE:Euro trading is green, but no volume

yeah because its declined 70 percent since the real companies posted their vaccine results... biovaxys does not have the resources or connections to get approved like phizer and moderna

<< Previous

Bullboard Posts

Next >>

AtkinsRéalis adds up to £90M in U.K.-based revenue